Triiodothyronine Promotes Cell Proliferation of Breast Cancer via Modulating miR-204/Amphiregulin.
AREG
Breast cancer
Cell viability
T3
miR-204
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
20
09
2018
accepted:
25
10
2018
pubmed:
9
11
2018
medline:
14
6
2019
entrez:
9
11
2018
Statut:
ppublish
Résumé
Breast cancer (BC) severely threatens women's life, and Triiodothyronine (T3) shows a positive role on BC cell proliferation, while the potential mechanism underlying it is still unclear. T3 was used to stimulate BC cell lines MCF-7 and T47-D. Real-time PCR was performed to determine the expression of miRNAs, while western blot was used to measure protein expression of Amphiregulin (AREG), AKT and p-AKT. The interaction between miR-204 and AREG was determined using luciferase reporter assay. MTT was performed to detect cell viability. The expression of miR-204 was decreased, while AREG and p-AKT was increased in T3 stimulated BC cell lines. T3 stimulation promoted cell viability. miR-204 targets AREG to regulate its expression. T3 promoted expression of AREG and p-AKT, while miR-204 overexpression reversed the effect of T3, however, pcDNA-AREG transfection abolished the effect of miR-204 mimic. T3 promoted cell viability of BC cells via modulating the AKT signaling pathway. The detailed mechanism was that the down-regulated miR-204 that induced by T3 stimulation promoted the expression of AREG, the up-regulated AREG activated AKT signaling pathway, while the activated AKT signaling promoted cell proliferation.
Identifiants
pubmed: 30406874
doi: 10.1007/s12253-018-0525-2
pii: 10.1007/s12253-018-0525-2
doi:
Substances chimiques
AREG protein, human
0
Amphiregulin
0
MIRN204 microRNA, human
0
MicroRNAs
0
Triiodothyronine
06LU7C9H1V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
653-658Références
Oncogene. 2002 Jan 24;21(5):761-8
pubmed: 11850804
Cancer Res. 2004 Feb 15;64(4):1522-33
pubmed: 14973112
Braz J Med Biol Res. 2005 May;38(5):761-5
pubmed: 15917958
Ann Oncol. 2006 Jan;17(1):60-4
pubmed: 16282247
Nat Cell Biol. 2008 Feb;10(2):202-10
pubmed: 18193036
J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):57-66
pubmed: 18328691
Cancer Res. 2008 Apr 1;68(7):2259-65
pubmed: 18381432
J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):171-9
pubmed: 18437539
Endocr Rev. 2008 Dec;29(7):898-938
pubmed: 18815314
Endocrinology. 2009 Jun;150(6):2957-63
pubmed: 19196796
Breast Cancer Res Treat. 2011 Nov;130(2):663-79
pubmed: 21814748
J Surg Oncol. 2012 Sep 1;106(3):260-6
pubmed: 22105810
Mol Oncol. 2012 Aug;6(4):458-72
pubmed: 22578566
Cell Death Dis. 2012 Nov 15;3:e423
pubmed: 23152059
Biochem Biophys Res Commun. 2014 Mar 7;445(2):314-9
pubmed: 24508260
ScientificWorldJournal. 2014 Jan 23;2014:969404
pubmed: 24587767
Int J Cancer. 2014 Sep 15;135(6):1356-68
pubmed: 24615544
Cancer Res. 2014 Aug 1;74(15):4145-56
pubmed: 24876105
Int J Clin Exp Pathol. 2014 May 15;7(6):3287-92
pubmed: 25031750
PLoS One. 2015 Jul 02;10(7):e0132399
pubmed: 26134825
J Cancer Res Clin Oncol. 2016 Jan;142(1):157-65
pubmed: 26195282
Cancer Biomark. 2015;15(5):535-42
pubmed: 26406941
Int J Mol Med. 2015 Dec;36(6):1720-6
pubmed: 26497897
Oncol Rep. 2017 Jul;38(1):368-376
pubmed: 28534958
Phytother Res. 2018 Nov;32(11):2214-2225
pubmed: 30069933
J Cell Physiol. 2018 Jan;234(1):769-776
pubmed: 30076720
J Cell Biochem. 2018 Nov;119(11):8773-8783
pubmed: 30076753
Biochimie. 2018 Nov;154:10-18
pubmed: 30076901
J Cell Physiol. 2018 Jan;234(1):632-641
pubmed: 30078180
Cell Biol Int. 2018 Aug 6;:null
pubmed: 30080301
Int J Cancer. 1997 Mar 17;70(6):722-6
pubmed: 9096655